EIF4G2抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Hela cells, HepG2 cells, NIH/3T3 cells, Primary antibody: P10807(EIF4G2 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

The eukaryotic initiation factor 4G2 (EIF4G2), also known as p97. DAP5. or NAT1. is a key component of the translation initiation machinery. Unlike its homolog EIF4G1. which supports cap-dependent translation, EIF4G2 facilitates cap-independent translation under stress conditions, such as nutrient deprivation, hypoxia, or viral infection. It functions by interacting with other initiation factors (e.g., eIF4A, eIF3) and recruiting ribosomes to internal ribosome entry sites (IRES) in specific mRNAs, enabling the synthesis of proteins critical for cell survival, apoptosis, or stress adaptation.

EIF4G2 antibodies are essential tools for studying translational regulation, particularly in contexts like cancer, neurodegeneration, and viral pathogenesis. These antibodies are used in techniques such as Western blotting, immunofluorescence, and immunoprecipitation to detect EIF4G2 expression, localization, and interactions. Researchers often validate their specificity using knockout cells or siRNA-mediated knockdown to confirm signal loss.

Dysregulation of EIF4G2 is linked to tumor progression, chemoresistance, and viral replication mechanisms, making it a potential therapeutic target. Antibodies targeting EIF4G2 help elucidate its role in cellular stress responses and disease pathways. Commercial EIF4G2 antibodies are typically raised in rabbits or mice, with epitopes spanning conserved regions of the protein. Proper controls and validation remain critical due to homology with EIF4G1 and cross-reactivity risks.